

# Copper Catalyzed C-H Functionalization for Direct Mannich Reactions

Magnus Rueping\* and Nikita Tolstoluzhsky

Magnus.Rueping@RWTH-Aachen.de

## Supporting Information

### CONTENT


1. General experimental details
2. General procedure for the synthesis
3. Experimental data for products
4. <sup>1</sup>H- and <sup>13</sup>C-NMR spectra of the products

**1. General experimental details.** Unless otherwise noted, all commercially available compounds were used as provided without further purification. All known imines as well as the new compounds **2e**, **2g** were prepared according to the literature.<sup>1</sup> All azaarenes except 2-(4-methoxyphenyl)-4-methylpyridine **6**,<sup>2</sup> are commercially available compounds. Solvents for chromatography were technical grade and distilled prior to use. Tetrahydrofuran used in reactions was reagent grade and distilled from sodium. Analytical thin-layer chromatography (TLC) was performed on Merck silica gel aluminum plates with F-254 indicator, visualized by irradiation with UV light. Column chromatography was performed using silica gel Merck 60 (particle size 0.063–0.2 mm), Sigma-Aldrich Co. Solvent mixtures are understood as volume/volume. <sup>1</sup>H- and <sup>13</sup>C-NMR were recorded on a Bruker AV 300 and Varian Inova 400 NMR spectrometer with CDCl<sub>3</sub> as solvent. Data are reported in the following order: chemical shift (δ) in ppm; multiplicities are indicated as br s (broadened singlet), s (singlet), d (doublet), t (triplet), m (multiplet); coupling constants (J) are in Hertz (Hz). Mass spectra (MS-ESI) were conducted on VG-Plattform II (Fisons Instruments) (column: Hypersil ODS 150 x 0.32 mm, 3 μm). IR spectra were recorded on a Jasco FT/IR-420 and a Perkin Elmer Spectrum 100 spectrometer and are reported in terms of frequency of absorption (cm<sup>-1</sup>).

**2. General procedure for the synthesis.** Under Argon, Cu(OTf)<sub>2</sub> (5.4 mg, 5 mol %), 1,10-phenanthroline (2.7 mg, 5 mol %), azaarene **1a** (81 mg, 0.76 mmol) and imine **2a** (79 mg, 0.304 mmol) were mixed in a screw cap vial and then dry THF (0.2 mL) was added. The mixture was stirred at 120 °C in a closed reaction vessel. The reaction was monitored by TLC. After completion of the reaction, the solvent was evaporated under reduced pressure and the residue purified by column chromatography on silica gel to give the desired product.


### 3. Experimental characterization data for products.

#### 4-bromo-N-(4-methoxybenzylidene)benzenesulfonamide **2e**:




The title compound was prepared according to the literature<sup>1</sup> and purified by recrystallization from EtOAc-Pentane, 90% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 3.89 (s, 3H), 6.97 (d, *J* = 8.9 Hz, 2H), 7.67 (d, *J* = 8.6 Hz, 2H), 7.80–7.93 (m, 4H), 8.95 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 55.71, 114.77, 125.00, 128.42, 129.34, 132.35, 133.92, 137.92, 165.57, 169.94; MS (ESI) calcd for C<sub>14</sub>H<sub>12</sub>BrNO<sub>3</sub>S [M+1]: 356.0, found: 356.0; IR (solid): ν = 1596, 1508, 1321, 1251, 1151, 1084, 1013, 803, 734 cm<sup>-1</sup>.

#### 4-methyl-N-((perfluorophenyl)methylene)benzenesulfonamide **2g**:




The title compound was prepared according to the literature<sup>1</sup> and purified by recrystallization from EtOAc-Pentane, 40% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.45 (s, 3H), 7.37 (d, *J* = 8.2 Hz, 2H), 7.89 (d, *J* = 8.2 Hz, 2H), 9.20 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 21.70, 128.41, 129.98, 133.87, 145.41, 158.53; <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -135.94, -142.32, -159.74; MS (ESI) calcd for C<sub>14</sub>H<sub>8</sub>F<sub>5</sub>NO<sub>2</sub>S [M+1]: 350.0, found: 349.8; IR (solid): ν = 2325, 1651, 1598, 1492, 1418, 1319, 1161, 1086, 1014, 965, 831, 730, 684 cm<sup>-1</sup>.


#### 4-methyl-N-(2-(6-methylpyridin-2-yl)-1-phenylethyl)benzenesulfonamide **3a**:




The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-6:1), 80% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.33 (s, 3H), 2.58 (s, 3H), 2.91-3.05 (m, 2H), 4.58 (t, *J* = 7.9 Hz, 1H), 6.75 (d, *J* = 7.6 Hz, 1H), 6.98–7.08 (m, 3H), 7.14–7.2 (m, 5H), 7.38–7.47 (m, 3H), 7.52 (br s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 21.4, 24.2, 43.6, 58.1, 121.0, 121.7, 126.7, 126.9, 127.2, 128.2, 129.1, 137.5, 137.6, 141.0, 142.5, 156.8, 157.5; MS (ESI) calcd for C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>S [M+1]: 367.1, found: 367.0; IR (solid): ν = 2923, 1595, 1457, 1330, 1157, 1090, 1044, 939, 794, 697 cm<sup>-1</sup>.

**N-(2-(6-methylpyridin-2-yl)-1-phenylethyl)benzenesulfonamide 3b:**

The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-5:1), 80% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.48 (s, 3H), 2.89 (d, *J* = 6.5 Hz, 2H), 4.53 (t, *J* = 6.5 Hz, 1H), 6.65 (d, *J* = 7.6 Hz, 1H), 6.90 (d, *J* = 7.7 Hz, 1H), 7.02–7.11 (m, 5H), 7.12–7.20 (m, 2H), 7.25–7.34 (m, 2H), 7.47 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.54 (br s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 24.30, 43.67, 58.16, 120.95, 121.65, 126.70, 126.87, 127.28, 128.19, 128.47, 131.87, 137.36, 140.52, 140.91, 156.81, 157.58; MS (ESI) calcd for C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S [M+1]: 353.1, found: 353.1; IR (solid): ν = 3382, 1592, 1454, 1321, 1156, 1091, 950, 753, 691 cm<sup>-1</sup>.


**N-(1-(4-methoxyphenyl)-2-(6-methylpyridin-2-yl)ethyl)benzenesulfonamide 3c:**

The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-6:1), 60% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.58 (s, 3H), 2.89–3.03 (m, 2H), 3.73 (s, 3H), 4.56 (dd, *J* = 8.2, 4.8 Hz, 1H), 6.67 (d, *J* = 8.8 Hz, 2H), 6.76 (d, *J* = 7.6 Hz, 1H), 7.00 (d, *J* = 7.7 Hz, 1H), 7.07 (d, *J* = 8.8 Hz, 2H), 7.21–7.28 (m, *J* = 7.6 Hz, 2H), 7.34–7.46 (m, 2H), 7.51–7.61 (m, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 24.19, 43.66, 55.21, 57.68, 113.58, 121.03, 121.71, 126.89, 127.87, 128.42, 131.79, 133.00, 137.53, 140.63, 156.88, 157.50, 158.75; MS (ESI) calcd for C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>S [M+1]: 383.1, found: 383.0; IR (solid): ν = 3382, 1589, 1512, 1453, 1321, 1246, 1156, 1092, 1032, 950, 831, 753, 688 cm<sup>-1</sup>.

**N-(1-(4-methoxyphenyl)-2-(6-methylpyridin-2-yl)ethyl)-4-nitrobenzenesulfonamide 3d:**

The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-5:1), 61% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.55 (s, 3H), 2.88–3.09 (m, 2H), 3.64 (s, 3H), 4.61 (dd, *J* = 8.9, 4.4 Hz, 1H), 6.55 (d, *J* = 8.7 Hz, 2H), 6.79 (d, *J* = 7.6 Hz, 1H), 6.91 (d, *J* = 8.7 Hz, 2H), 7.01 (d, *J* = 7.8 Hz, 1H), 7.45 (t, *J* = 7.7 Hz, 1H), 7.57 (d, *J* = 8.6 Hz, 2H), 7.97 (d, *J* = 8.6 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 24.07, 43.05, 55.23, 58.03, 113.58, 121.23, 122.03, 123.46, 128.09, 128.13, 132.00, 137.92, 146.90, 149.25, 156.73, 157.49, 159.10; MS (ESI) calcd for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub>S [M+1]: 428.1, found: 428.0; IR (CDCl<sub>3</sub>): ν = 3581, 3379, 3025, 1604, 1525, 1458, 1346, 1249, 1161, 1093, 1034, 956, 834, 753, 687, 616, 557 cm<sup>-1</sup>.


#### 4-bromo-N-(1-(4-methoxyphenyl)-2-(6-methylpyridin-2-yl)ethyl)benzenesulfonamide 3e:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-5:1), 75% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.51 (s, 3H), 2.85–2.95 (m, 2H), 3.68 (s, 3H), 4.46–4.57 (m, 1H), 6.60 (d, *J* = 8.7 Hz, 2H), 6.72 (d, *J* = 7.6 Hz, 1H), 6.89–7.02 (m, 3H), 7.28 (s, 4H), 7.38 (t, *J* = 7.7 Hz, 1H), 7.65 (br s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 24.24, 43.53, 55.26, 57.80, 113.58, 121.04, 121.75, 126.53, 128.00, 128.50,

131.54, 132.53, 137.54, 139.93, 156.89, 157.58, 158.91; MS (ESI) calcd for C<sub>21</sub>H<sub>21</sub>BrN<sub>2</sub>O<sub>3</sub>S [M+1]: 463.0, found: 462.8; IR (solid): ν = 3258, 2923, 2854, 1734, 1613, 1579, 1512, 1453, 1326, 1250, 1154, 1065, 960, 818, 737 cm<sup>-1</sup>.


#### 4-methyl-N-(2-(6-methylpyridin-2-yl)-1-(4-(trifluoromethyl)phenyl)ethyl)benzene-sulfonamide 3f:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-5:1), 80% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.23 (s, 3H), 2.49 (s, 3H), 2.80–2.90 (m, 2H), 4.58 (t, *J* = 6.4 Hz, 1H), 6.67 (d, *J* = 7.6 Hz, 1H), 6.89–6.99 (m, 3H), 7.20 (d, *J* = 8.8 Hz, 2H), 7.26–7.40 (m, 5H), 7.66 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 21.27, 24.23, 43.13, 57.64, 121.01, 121.83, 125.08 (q, *J*<sup>F</sup> = 3.7 Hz), 126.91, 127.19, 129.15, 137.28,

137.50, 142.88, 145.01, 156.24, 157.71; <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -62.62; MS (ESI) calcd for C<sub>22</sub>H<sub>21</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S [M+1]: 435.1, found: 435.1; IR (solid): ν = 2927, 1595, 1459, 1322, 1158, 919, 819, 712, 661 cm<sup>-1</sup>.


#### 4-methyl-N-(2-(6-methylpyridin-2-yl)-1-(perfluorophenyl)ethyl)benzene-sulfonamide 3g:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-5:1), 79% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.34 (s, 3H), 2.48 (s, 3H), 3.02 (dd, *J* = 14.0, 5.5 Hz, 1H), 3.29 (dd, *J* = 13.9, 9.1 Hz, 1H), 4.95–5.10 (m, 1H), 6.70 (br s, 1H), 6.82 (d, *J* = 7.6 Hz, 1H), 6.99 (d, *J* = 7.7 Hz, 1H), 7.10 (d, *J* = 7.9 Hz, 2H), 7.43 (t, *J* = 7.7 Hz, 1H), 7.50 (d, *J* = 8.3 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 21.30, 24.13,

41.04, 48.68, 120.54, 121.90, 126.89, 129.19, 136.44, 137.28, 143.39, 155.21, 158.07; <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -142.39, -154.93, -162.05; MS (ESI) calcd for C<sub>21</sub>H<sub>17</sub>F<sub>5</sub>N<sub>2</sub>O<sub>2</sub>S [M+1]: 457.1, found: 457.1; IR (solid): ν = 3068, 2327, 1651, 1595, 1503, 1460, 1409, 1362, 1312, 1150, 998, 944, 856, 803, 708, 660 cm<sup>-1</sup>.


#### 4-methyl-N-(2-(6-methylpyridin-2-yl)-1-(4-nitrophenyl)ethyl)benzenesulfonamide 3h:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-2:1), 97% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.33 (s, 3H), 2.56 (s, 3H), 2.91–3.03 (m, 2H), 4.67 (t, *J* = 6.3 Hz, 1H), 6.72 (d, *J* = 7.6 Hz, 1H), 7.02 (d, *J* = 7.7 Hz, 1H), 7.08 (d, *J* = 8.4 Hz, 2H), 7.34–7.42 (m, 3H), 7.43–7.50 (m, 2H), 7.86 (br s, 1H), 8.02 (d, *J* = 8.8 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 21.39, 24.20, 42.75, 57.36, 121.06,


122.02, 123.45, 126.89, 127.65, 129.32, 137.08, 137.67, 143.20, 147.05, 148.67, 155.79, 157.76; MS (ESI) calcd for  $C_{21}H_{21}N_3O_4S$  [M+1]: 412.1, found: 412.1; IR (solid):  $\nu = 2923, 1597, 1518, 1458, 1337, 1155, 1062, 942, 854, 814, 666\text{ cm}^{-1}$ .

#### N-(1-(2-bromophenyl)-2-(6-methylpyridin-2-yl)ethyl)-4-methylbenzenesulfonamide 3i:




The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-2:1), 88% yield.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.32 (s, 3H), 2.59 (s, 3H), 2.84 (dd,  $J = 13.9, 9.3\text{ Hz}$ , 1H), 3.00 (dd,  $J = 13.9, 3.7\text{ Hz}$ , 1H), 4.87 (d,  $J = 7.6\text{ Hz}$ , 1H), 6.74 (d,  $J = 7.6\text{ Hz}$ , 1H), 7.00 (d,  $J = 7.7\text{ Hz}$ , 1H), 7.06 (d,  $J = 8.6\text{ Hz}$ , 3H), 7.15 (td,  $J = 7.6, 1.3\text{ Hz}$ , 1H), 7.37 (d,  $J = 7.7\text{ Hz}$ , 1H), 7.39–7.43 (m, 1H), 7.47 (d,  $J = 8.2\text{ Hz}$ , 3H), 7.56 (br s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  21.41, 24.20, 41.66, 57.29, 120.83, 121.75, 121.91, 127.00, 127.48, 128.68, 128.93, 129.16, 132.50, 136.60, 137.58, 140.18, 142.74, 156.43, 157.42; MS (ESI) calcd for  $C_{21}H_{21}\text{BrN}_2\text{O}_2\text{S}$  [M+1]: 447.1, found: 447.0; IR (solid):  $\nu = 2923, 1597, 1518, 1458, 1337, 1155, 1062, 942, 854, 814, 666\text{ cm}^{-1}$ .

#### 4-methyl-N-(2-(6-methylpyridin-2-yl)-1-(pyridin-3-yl)ethyl)benzenesulfonamide 3j:




The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-0:1), 89% yield.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.31 (s, 3H), 2.54 (s, 3H), 4.62 (s, 1H), 2.91–3.02 (m, 2H), 6.72 (d,  $J = 7.5\text{ Hz}$ , 1H), 6.99 (d,  $J = 7.7\text{ Hz}$ , 1H), 7.07 (d,  $J = 7.9\text{ Hz}$ , 3H), 7.39 (t,  $J = 7.7\text{ Hz}$ , 1H), 7.45 (d,  $J = 8.0\text{ Hz}$ , 2H), 7.52 (s, 1H), 7.84 (s, 1H), 8.40 (s, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  21.53, 24.39, 43.20, 55.75, 121.04, 121.80, 123.15, 126.85, 129.26, 134.46, 136.81, 137.10, 137.43, 142.88, 148.16, 148.41, 156.07, 157.62; MS (ESI) calcd for  $C_{20}H_{21}N_3O_2\text{S}$  [M+1]: 368.1, found: 368.0; IR (solid):  $\nu = 3070, 2869, 1578, 1458, 1426, 1329, 1153, 1067, 947, 814, 715, 667\text{ cm}^{-1}$ .

#### N-(1-(4-bromophenyl)-2-(6-methylpyridin-2-yl)ethyl)-4-methylbenzenesulfonamide 3k:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-2:1), 88% yield.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.28 (s, 3H), 2.50 (s, 3H), 2.81–2.93 (m, 2H), 4.48 (t,  $J = 6.2\text{ Hz}$ , 1H), 6.67 (d,  $J = 7.7\text{ Hz}$ , 1H), 6.89–7.05 (m, 5H), 7.13–7.25 (m, 2H), 7.30–7.40 (m, 3H), 7.57 (br s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  21.41, 24.17, 43.16, 57.46, 121.08, 121.12, 121.82, 126.93, 128.52, 129.16, 131.23, 137.41, 137.59, 140.07, 142.80, 156.37, 157.60; MS (ESI) calcd for  $C_{21}H_{21}\text{BrN}_2\text{O}_2\text{S}$  [M+1]: 447.1, found: 447.0; IR (solid):  $\nu = 3121, 1594, 1459, 1329, 1158, 1089, 1040, 925, 822, 729, 669\text{ cm}^{-1}$ .


#### N-(1-phenyl-2-(pyridin-2-yl)ethyl)benzenesulfonamide 4a:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (8:1-2:1), 50% yield.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.96–3.08 (m, 2H), 4.70 (dt,  $J = 7.1, 5.3\text{ Hz}$ , 1H), 6.88 (d,  $J = 7.7\text{ Hz}$ , 1H), 7.08–7.16 (m, 6H), 7.26 (t,  $J = 7.6\text{ Hz}$ ,


2H), 7.33 (d,  $J = 5.1$  Hz, 1H), 7.35–7.41 (m, 1H), 7.47 (td,  $J = 7.7, 1.8$  Hz, 1H), 7.56–7.62 (m, 2H), 8.48 (d,  $J = 4.2$  Hz, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  43.96, 57.92, 121.98, 124.05, 126.61, 126.92, 127.26, 128.20, 128.54, 131.92, 136.88, 140.70, 148.82, 157.56; MS (ESI) calcd for  $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_2\text{S}$  [ $\text{M}+1$ ]: 339.1, found: 339.0; IR (solid):  $\nu = 3063, 2856, 1596, 1444, 1311, 1148, 1061, 966, 862, 754, 684\text{ cm}^{-1}$ .

#### N-(2-(3-methylpyridin-2-yl)-1-phenylethyl)benzenesulfonamide 5a:




The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-6:1), 79% yield.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.96 (s, 3H), 2.98–3.07 (m, 2H), 4.63 (dd,  $J = 9.8, 6.1$  Hz, 1H), 7.03 (dd,  $J = 7.6, 4.8$  Hz, 1H), 7.10–7.15 (m, 5H), 7.20–7.31 (m, 3H), 7.33–7.44 (m, 2H), 7.55 (dd,  $J = 8.4, 1.2$  Hz, 2H), 8.32 (d,  $J = 4.3$  Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  18.54, 40.43, 57.06, 122.06, 126.51, 126.84, 127.25, 128.17, 128.47, 131.84, 131.97, 138.33, 140.39, 140.96, 145.98, 155.80; MS (ESI) calcd for  $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2\text{S}$  [ $\text{M}+1$ ]: 353.1, found: 353.0; IR (solid):  $\nu = 3026, 2852, 2712, 1582, 1447, 1319, 1155, 1062, 963, 799, 754, 688\text{ cm}^{-1}$ .

#### Ethyl 2-(2-phenyl-2-(phenylsulfonamido)ethyl)nicotinate 6a:




The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-4:1), 62% yield.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.31 (t,  $J = 7.1$  Hz, 3H), 3.25–3.41 (m, 2H), 4.29 (q,  $J = 7.1$  Hz, 2H), 4.67–4.87 (m, 1H), 6.69 (d,  $J = 5.7$  Hz, 1H), 7.05–7.20 (m, 6H), 7.21–7.32 (m, 3H), 7.36 (dd,  $J = 8.4, 1.3$  Hz, 2H), 8.00 (dd,  $J = 7.9, 1.4$  Hz, 1H), 8.49 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  14.20, 43.17, 58.10, 61.94, 121.78, 126.45, 126.64, 127.25, 128.34, 128.46, 131.63, 138.68, 140.41, 141.71, 151.60, 158.52, 166.67; MS (ESI) calcd for  $\text{C}_{22}\text{H}_{22}\text{N}_2\text{O}_4\text{S}$  [ $\text{M}+1$ ]: 411.1, found: 411.0; IR (solid):  $\nu = 3118, 2924, 1716, 1572, 1444, 1324, 1263, 1160, 1083, 942, 767, 692\text{ cm}^{-1}$ .

#### N-(1-phenyl-2-(pyridin-2-yl)propyl)benzenesulfonamide 7a:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-4:1), 58% yield. (D/R isomers ratio 9:1 according to NMR)  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.12–1.24 (m, 3H), 3.10–3.28 (m, 1H), 4.49–4.62 (m, 1H), 6.75 (d,  $J = 7.8$  Hz, 1H), 6.81–6.91 (m, 2H), 6.96–7.07 (m, 4H), 7.14–7.24 (m, 3H), 7.27–7.34 (m, 1H), 7.40 (td,  $J = 7.7, 1.8$  Hz, 1H), 7.50–7.59 (m, 2H), 8.46 (d,  $J = 4.3$  Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  15.34, 45.88, 62.32, 121.90, 122.48, 126.85, 127.00, 127.33, 127.65, 128.42, 131.82, 136.66, 138.73, 140.19, 148.43, 161.56; MS (ESI) calcd for  $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2\text{S}$  [ $\text{M}+1$ ]: 353.1, found: 353.0; IR (solid):  $\nu = 3296, 1591, 1445, 1317, 1156, 1089, 917, 752, 693\text{ cm}^{-1}$ .


#### N-(2-(5-ethylpyridin-2-yl)-1-phenylethyl)benzenesulfonamide 8a:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-5:1), 54% yield.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.16 (td,  $J = 7.6, 1.1$  Hz, 3H), 2.53 (q,  $J = 7.6$  Hz, 2H), 2.93 (d,  $J = 6.5$  Hz, 2H), 4.58 (s, 1H), 6.76 (d,  $J = 7.9$


Hz, 1H), 7.06 (s, 5H), 7.14–7.21 (m, 2H), 7.23–7.35 (m,  $J = 16.5, 7.8$  Hz, 3H), 7.50 (d,  $J = 8.4$  Hz, 2H), 8.26 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  15.14, 25.66, 43.40, 58.09, 123.65, 126.65, 126.93, 127.24, 128.18, 128.45, 131.83, 136.44, 137.59, 140.60, 140.82, 148.27, 154.69; MS (ESI) calcd for  $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_2\text{S}$  [ $\text{M}+1$ ]: 367.1, found: 367.0; IR (solid):  $\nu = 3055, 2854, 1576, 1488, 1444, 1314, 1150, 1063, 969, 839, 755, 689\text{ cm}^{-1}$ .

#### N-(2-(5-methylpyrazin-2-yl)-1-phenylethyl)benzenesulfonamide 9a:




The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (6:1-2:1), 49% yield.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.40 (s, 3H), 3.01 (d,  $J = 6.6$  Hz, 2H), 4.72 (q,  $J = 6.5$  Hz, 1H), 6.55 (d,  $J = 6.6$  Hz, 1H), 6.96–7.13 (m, 5H), 7.19 (t,  $J = 7.5$  Hz, 2H), 7.27–7.40 (m, 1H), 7.47–7.60 (m, 2H), 7.99 (s, 1H), 8.19 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  21.15, 41.18, 57.70, 126.45, 126.87, 127.53, 128.41, 128.61, 132.04, 132.12, 140.08, 140.49, 143.36, 143.87, 149.60, 151.99; MS (ESI) calcd for  $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_2\text{S}$  [ $\text{M}+1$ ]: 354.1, found: 354.0; IR (solid):  $\nu = 3072, 2872, 1692, 1491, 1446, 1313, 1150, 1062, 968, 844, 756, 691\text{ cm}^{-1}$ .

#### N-(1-phenyl-2-(pyridazin-3-yl)ethyl)benzenesulfonamide 10a:




The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (5:1-2:1-1:1-1:2), 58% yield.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.30 (qd,  $J = 14.2, 6.9$  Hz, 2H), 4.79 (td,  $J = 7.9, 5.3$  Hz, 1H), 6.81 (d,  $J = 7.3$  Hz, 1H), 7.05 (s, 5H), 7.09–7.27 (m, 4H), 7.26–7.37 (m, 1H), 7.45–7.58 (m, 2H), 8.94 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  43.14, 57.73, 126.52, 126.83, 126.93, 127.56, 127.75, 128.44, 128.64, 132.02, 139.94, 140.49, 149.96, 160.18; MS (ESI) calcd for  $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_2\text{S}$  [ $\text{M}+1$ ]: 340.1, found: 340.0; IR (solid):  $\nu = 3060, 2864, 1580, 1477, 1318, 1152, 1065, 945, 807, 747, 689\text{ cm}^{-1}$ .

#### N-(1-phenyl-2-(pyrimidin-4-yl)ethyl)benzenesulfonamide 11a:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (5:1-0:1), 50% yield.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.00–3.20 (m, 2H), 4.83 (dd,  $J = 13.0, 6.9$  Hz, 1H), 6.74 (d,  $J = 6.9$  Hz, 1H), 6.98 (s, 1H), 7.05–7.18 (m, 5H), 7.22–7.33 (m, 2H), 7.41 (ddd,  $J = 6.8, 3.9, 1.2$  Hz, 1H), 7.54–7.68 (m, 2H), 8.53 (s, 1H), 9.05 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  44.13, 57.11, 126.42, 126.84, 127.65, 128.47, 128.72, 132.25, 139.80, 140.34, 156.93, 157.93, 166.06; MS (ESI) calcd for  $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_2\text{S}$  [ $\text{M}+1$ ]: 340.1, found: 340.0; IR (solid):  $\nu = 3078, 2865, 1585, 1451, 1392, 1310, 1148, 1059, 958, 861, 821, 758, 687\text{ cm}^{-1}$ .


#### N-(1-phenyl-2-(quinoxalin-2-yl)ethyl)benzenesulfonamide 12a:



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (6:1-1:1), 76% yield.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.16–3.33 (m, 2H), 4.80 (q,  $J = 6.6$  Hz, 1H), 6.56 (d,  $J = 6.4$  Hz, 1H), 6.95–7.04 (m, 2H), 7.05–7.19 (m, 6H), 7.38–7.51 (m, 2H), 7.59–7.76 (m, 2H), 7.87–8.04 (m, 2H), 8.37 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,


CDCl<sub>3</sub>):  $\delta$  42.40, 57.63, 126.50, 126.64, 127.71, 128.45, 128.55, 128.89, 129.23, 129.69, 130.37, 132.01, 140.07, 140.25, 141.41, 145.63, 152.76; MS (ESI) calcd for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>S [M+1]: 390.1, found: 390.0; IR (solid):  $\nu$  = 3267, 3061, 2926, 1494, 1448, 1315, 1151, 1092, 1051, 983, 948, 902, 835, 754, 721, 689 cm<sup>-1</sup>.

#### N-(2-(6-bromoquinolin-2-yl)-1-phenylethyl)benzenesulfonamide **13a**:




The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-6:1), 63% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  3.14 (d,  $J$  = 6.6 Hz, 2H), 4.69 (dd,  $J$  = 11.9, 6.5 Hz, 1H), 6.96 (d,  $J$  = 8.4 Hz, 1H), 6.99–7.16 (m, 8H), 7.17–7.24 (m, 1H), 7.40–7.46 (m, 2H), 7.69–7.80 (m, 2H), 7.81–7.90 (m, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  44.40, 57.83, 120.53, 122.87, 126.61, 126.72, 127.51, 127.96, 128.39, 129.60, 130.00, 131.84, 133.65, 136.51, 140.29, 140.63, 158.46; MS (ESI) calcd for C<sub>23</sub>H<sub>19</sub>BrN<sub>2</sub>O<sub>2</sub>S [M+1]: 469.0, found: 468.9; IR (solid):  $\nu$  = 3255, 3064, 1593, 1489, 1450, 1319, 1157, 1091, 1056, 945, 880, 826, 722, 688 cm<sup>-1</sup>.

#### N-(1-phenyl-2-(quinolin-2-yl)ethyl)benzenesulfonamide **14a**:



Under Argon, Cu(OTf)<sub>2</sub> (5.4 mg, 5 mol %), 1,10-phenanthroline (2.7 mg, 5 mol %), quinaldine **3l** (0.32 mmol), imine **2a** (79 mg, 0.304 mmol) and iPr<sub>2</sub>NEt 1.5 eq. were mixed in a screw cap vial and then dry THF (0.2 mL) was added. The mixture was stirred at 120 °C and monitored by TLC, after the completion of the reaction, the solvent was evaporated under reduced pressure and the residue was purified by column chromatography: first column Hexane-EtOAc (10:1-5:1), second column Hexane-2-Propanol (25:1), 55 % yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  3.03–3.27 (m, 2H), 4.64 (dt,  $J$  = 8.0, 5.0 Hz, 1H), 6.90–7.03 (m, 3H), 7.04–7.26 (m, 6H), 7.34–7.44 (m, 3H), 7.44–7.52 (m, 1H), 7.60–7.75 (m, 2H), 7.89 (d,  $J$  = 8.4 Hz, 1H), 8.04 (d,  $J$  = 8.9 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  44.41, 57.95, 121.85, 126.63, 126.67, 126.75, 126.89, 127.43, 127.59, 131.75, 128.32, 128.35, 128.51, 130.20, 137.43, 140.17, 140.96, 146.75, 158.00; MS (ESI) calcd for C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S [M+1]: 389.1, found: 389.0; IR (solid):  $\nu$  = 3054, 2862, 1601, 1565, 1504, 1434, 1324, 1260, 1158, 1055, 956, 821, 755, 723, 690 cm<sup>-1</sup>.


#### N-(2-(4-methylpyridin-2-yl)-1-phenylethyl)benzenesulfonamide **15a**:



The title compound and **4nb** was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-7:1) for **3nb** and Hexane-EtOAc (7:1-1:1) for **4nb**, 23 % yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  2.15 (s, 3H), 2.92 (d,  $J$  = 6.1 Hz, 2H), 4.57 (s, 1H), 6.68 (s, 1H), 6.90 (s, 1H), 7.07 (s, 5H), 7.13–7.25 (m, 3H), 7.27–7.41 (m, 2H), 7.45–7.55 (m, 2H), 8.28 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  21.16, 43.20, 58.16, 126.64, 126.87, 127.36, 128.26, 128.45, 131.80, 140.59, 147.13, 149.87, 156.68; MS (ESI) calcd for C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S [M+1]: 353.1, found: 353.0; IR (solid):  $\nu$  = 3060, 2855, 2718, 1610, 1446, 1317, 1153, 1090, 1061, 967, 824, 754, 690 cm<sup>-1</sup>.




**N-(2-(2-methylpyridin-4-yl)-1-phenylethyl)benzenesulfonamide 15b:**



The title compound and **3nb** was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-7:1) for **3nb** and Hexane-EtOAc (7:1-1:1) for **4nb**, 55 % yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H), 2.92 (qd, J = 13.8, 7.4 Hz, 2H), 4.50 (q, J = 7.5 Hz, 1H), 6.01 (d, J = 7.7 Hz, 1H), 6.66 (d, J = 3.9 Hz, 1H), 6.73 (s, 1H), 6.92–7.00 (m, 2H), 7.00–7.11 (m, 3H), 7.12–7.24 (m, 2H), 7.28–7.40 (m, 1H), 7.44–7.58 (m, 2H), 8.14 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 23.74, 43.15, 58.72, 121.96, 124.53, 126.54, 126.75, 127.77, 128.50, 128.69, 132.31, 139.58, 140.15, 147.17, 148.08, 157.76; MS (ESI) calcd for C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S [M+1]: 353.1, found: 353.0; IR (CDCl<sub>3</sub>): ν = 3278, 3064, 2858, 1608, 1449, 1323, 1159, 1091, 957, 912, 754, 580, 548 cm<sup>-1</sup>.

**N-(2-(2-(4-methoxyphenyl)pyridin-4-yl)-1-phenylethyl)benzenesulfonamide 16a:**



The title compound was prepared according to the General Procedure and purified by column chromatography Hexane-EtOAc (10:1-6:1), 48 % yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.97 (qd, J = 13.8, 7.3 Hz, 2H), 3.77 (s, 3H), 4.54 (q, J = 7.4 Hz, 1H), 5.73 (d, J = 7.5 Hz, 1H), 6.68 (d, J = 5.1, 1.2 Hz, 1H), 6.87 (d, J = 8.8 Hz, 2H), 6.94–7.01 (m, 2H), 7.04–7.10 (m, 3H), 7.11–7.19 (m, 3H), 7.28 (t, J = 7.4 Hz, 1H), 7.50 (d, J = 7.3 Hz, 2H), 7.73 (d, J = 8.7 Hz, 2H), 8.30 (d, J = 5.1 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 43.40, 55.34, 58.64, 114.09, 120.88, 122.35, 126.57, 126.75, 127.81, 128.29, 128.57, 128.72, 131.15, 132.37, 139.61, 140.00, 146.81, 148.99, 156.76, 160.58; MS (ESI) calcd for C<sub>26</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub>S [M+1]: 445.2, found: 445.1; IR (CDCl<sub>3</sub>): ν = 3268, 3029, 2930, 1721, 1606, 1514, 1459, 1318, 1248, 1160, 1071, 962, 841, 756, 584 cm<sup>-1</sup>.

